scholarly journals Efficacy of current treatments against hepatitis C virus

2022 ◽  
Author(s):  
Jose M. Zepeda ◽  
Alejandro Murrieta ◽  
Javier Contreras ◽  
Felix Osuna ◽  
Luis Antonio Villalobos Calderon ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Protease Inhibitors ◽  
Mutation Rate ◽  
Humoral Immunity ◽  
Etiological Agent ◽  
Hcv Therapy ◽  
The World ◽  
At Risk Populations

It is estimated that currently, in the world, approximately 3% of the population has chronic hepatitis, the hepatitis C virus is the etiological agent most related to the development of this pathology. The diversity of genotypes (7) and quasi-species of HCV, due to its high mutation rate, interferes with an effective humoral immunity. The aim of this work is precisely to evoke those usual drugs used in HCV therapy, as well as cutting-edge drugs. The goal of treatment is the eradication of HCV infection. One strategy offered by the WHO is to eradicate the virus in at-risk populations. Alternatives to the previously used treatment with interferon and ribavirin are shown in this paper; protease inhibitors and other targets have now been developed to make eradication of the virus more effective.

scholarly journals IFN-λ: A New Class of Interferon with Distinct Functions-Implications for Hepatitis C Virus Research

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Bing Liu ◽  
Ian McGilvray ◽  
Limin Chen
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Outcomes ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Nucleotide Polymorphisms ◽  
Hcv Therapy ◽  
Virus Research ◽  
Type Iii Ifn

Pegylated interferon-αand ribavirin (PEG-IFN/RBV) is widely used to treat chronic hepatitis C virus infection with notorious adverse reactions since the broad expression of IFN-αreceptors on all nucleated cells. Accordingly, a Type III IFN with restricted receptors distribution is much safer as an alternative for HCV therapy. In addition, single nucleotide polymorphisms (SNPs) near the humanIFN-λ3gene,IL-28B, correlate strongly with the ability to achieve a sustained virological response (SVR) to therapy with pegylated IFN-αplus ribavirin in patients infected with chronic hepatitis C. Furthermore, we also discuss the most recent findings:IFN-λ4predicts treatment outcomes of HCV infection. In consideration of the apparent limitations of current HCV therapy, especially high failure rate and universal side effects, prediction of treatment outcomes prior to the initiation of treatment and developing new alternative drugs are two important goals in HCV research.

PS-030 Safety assessment of protease inhibitors in the treatment of chronic hepatitis C virus infection

2014 ◽  
Vol 21 (Suppl 1) ◽  
pp. A155.3-A156
Author(s):  
M Gayoso Rey ◽  
C Arroyo Conde ◽  
A Cendón Otero ◽  
M López-Gil Otero ◽  
B Leboreiro Enríquez ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Protease Inhibitors ◽  
Chronic Hepatitis C ◽  
Safety Assessment ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus

Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients

2015 ◽  
Vol 36 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Francesca Lupo ◽  
Roberta Russo ◽  
Achille Iolascon ◽  
Donatella Ieluzzi ◽  
Angela Siciliano ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Protease Inhibitors ◽  
Chronic Hepatitis C ◽  
Ineffective Erythropoiesis ◽  
Chronic Hepatitis C Virus
Sign in / Sign up

Export Citation Format

Share Document